• ثبت نام
    • ورود به سامانه
    مشاهده مورد 
    •   صفحهٔ اصلی
    • نشریات انگلیسی
    • Iranian Journal of Pharmaceutical Research
    • Volume 15, Issue 1
    • مشاهده مورد
    •   صفحهٔ اصلی
    • نشریات انگلیسی
    • Iranian Journal of Pharmaceutical Research
    • Volume 15, Issue 1
    • مشاهده مورد
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Administrative Process and Criteria Ranking for Drug Entering Health Insurance List in Iran-TOPSIS-Based Consensus Model

    (ندگان)پدیدآور
    viyanchi, amirGhatari, AliRasekh, HamidSafikhani, Hamidreza
    Thumbnail
    دریافت مدرک مشاهده
    FullText
    اندازه فایل: 
    1.308 مگابایت
    نوع فايل (MIME): 
    PDF
    نوع مدرک
    Text
    Research article
    زبان مدرک
    English
    نمایش کامل رکورد
    چکیده
    The purposes of our study were to identify a drug entry process, collect, and prioritize criteria for selecting drugs for the list of basic health insurance commitments to prepare an “evidence based reimbursement eligibility plan" in Iran.The 128 noticeable criteria were found when studying the health insurance systems of developed countries. Four parts (involving criteria) formed the first questionnaire: evaluation of evidences quality, clinical evaluation, economic evaluation, and managerial appraisal. The 85 experts (purposed sampling) were asked to mark the importance of each criterion from 1 to 100 as 1 representing the least and 100 the most important criterion and 45 out of them replied completely. Then, in the next questionnaire, we evaluated the 48 remainder criteria by the same45 participants under four sub-criteria (Cost calculation simplicity, Interpretability, Precision, and Updating capability of a criterion). After collecting the replies, the remainder criteria were ranked by TOPSIS method. Softwares “SPSS" 17 and Excel 2007 were used. The ranks of the five most important criteria which were found for drug approval based on TOPSIS are as follows: 1-domestic production (0.556), 2-duration of using (0.399), 3-independence of the assessment group (0.363) 4-impact budgeting (0.362) 5-decisions of other countries about the same drug (0.358). The numbers in parenthesis are relative closeness alternatives in relation to the ideal solution. This model gave a scientific model for judging fairly on the acceptance of novelty medicines.
    کلید واژگان
    Health Insurance
    Criteria Reimbursement
    Decision Making
    Iran
    Pharmacutics

    شماره نشریه
    1
    تاریخ نشر
    2016-02-01
    1394-11-12
    ناشر
    School of Pharmacy, Shahid Beheshti University of Medical Sciences
    سازمان پدید آورنده
    Shahid Beheshti University of Medical Scineces,Tehran,Iran.
    Tarbiat Modares University
    Shahid Beheshti university of medical sciences
    Member of Strategic Council at National Research Network for Policy Making, Economics & Health Management

    شاپا
    1735-0328
    1726-6890
    URI
    https://dx.doi.org/10.22037/ijpr.2016.1800
    http://ijpr.sbmu.ac.ir/article_1800.html
    https://iranjournals.nlai.ir/handle/123456789/312035

    مرور

    همه جای سامانهپایگاه‌ها و مجموعه‌ها بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌هااین مجموعه بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌ها

    حساب من

    ورود به سامانهثبت نام

    آمار

    مشاهده آمار استفاده

    تازه ترین ها

    تازه ترین مدارک
    © کليه حقوق اين سامانه برای سازمان اسناد و کتابخانه ملی ایران محفوظ است
    تماس با ما | ارسال بازخورد
    قدرت یافته توسطسیناوب